YARDLEY, Pa., Feb. 28, 2018 /PRNewswire/ -- Heraeus Medical, a global leader in joint fixation and infection management announced today the introduction of innovations to its current PALACOS® product portfolio. The exciting new products include the medium viscosity bone cement PALACOS MV variations, along with two mixing systems, PALAMIX® and PALABOWL®.
The innovative PALAMIX® and PALABOWL®, while created for use with PALACOS® bone cement, can be effectively used with other types of bone cements. These new products, along with the complete PALACOS® portfolio, will be displayed during the American Academy of Orthopedic Surgeons' Annual Meeting, March 6-10, 2018 in New Orleans. AAOS attendees wanting to learn more about the medium viscosity bone cement, versatile mixing options or view other ground-breaking products are encouraged to visit Heraeus Medical at booth 1713 and participate in demonstrations and discussions.
"The collaborative environment of AAOS provides an excellent opportunity to share our newest technologies with total joint arthroplasty surgeons and gain direct feedback," said Devin Childers, Vice President and General Manager of Heraeus Medical LLC. "Heraeus is excited to share our rapidly growing portfolio with attendees."
In January, the company announced it would provide PALACOS® customers with earlier access to its latest technologies by selling to them directly. PALACOS®, formerly sold exclusively through a distributor in the US, is now available directly through its pioneer and manufacturer, Heraeus Medical.
New and existing PALACOS® customers in the US are able to order products directly from Heraeus Medical by calling 1-833-PALACOS (725-2267). Heraeus Medical has successfully sold and supported PALACOS® customers directly in Europe, Australia, and several other countries through an integrated ordering process that is now also available to US customers.
For more information or to order PALACOS® in the US, please visit www.heraeus-medical-usa.com or call 1-833-PALACOS (725-2267).
For more information during AAOS, please visit Heraeus Medical at booth 1713.
About the Heraeus Medical Global Business Unit
Heraeus Medical is known as a global leader in joint fixation and infection management in orthopedics and trauma surgery. This enables the company to make an important contribution to supporting surgeons and the surgical team and to improve surgery outcomes. In the area of biomaterials, Heraeus Medical focuses on products for use in bone and joint surgery. The core product PALACOS® is considered the gold standard among bone cements and has repeatedly proven itself over five decades of clinical use.
Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned company formed in 1851. With expertise, a focus on innovations, operational excellence and an entrepreneurial leadership, we strive to continuously improve the businesses of our customers around the world.
We create high-quality solutions for our customers and strengthen their long-term competitiveness by combining material expertise with technological know-how. Our ideas are focused on important issues such as the environment, energy, health, mobility, and industrial applications. Our portfolio ranges from components to coordinated material systems which are used in a wide variety of industries, including the steel, electronics, chemical, automotive, and telecommunications industries.
In the 2016 financial year, the FORTUNE Global 500 listed company-generated revenues without precious metals of US$2.2 bn and a total revenue of US$23.8 bn. With approximately 12,400 employees worldwide in more than 100 subsidiaries in 40 countries, Heraeus holds a leading position in its global markets. In 2016, the Foundation for Family Businesses named Heraeus as one of the "Top 10 Family Businesses" in Germany.
View original content with multimedia:http://www.prnewswire.com/news-releases/heraeus-medical-to-introduce-medium-viscosity-bone-cement-and-vacuum-mixing-system-innovations-at-aaos-2018-annual-meeting-300605260.html
SOURCE Heraeus Medical